Reviewed by Jonathan Teplitsky · Updated August 2026 · Informational only — not legal or medical advice; Rank and Pay is not affiliated with the VA.
Respiratory cancer is a PACT Act presumptive cancer
Lung cancer and other respiratory-system cancers are on VA's list of presumptive cancers under the PACT Act for veterans with qualifying burn-pit and airborne-hazard exposure. Presumptive status removes the hardest part of the claim: you do not have to prove that burn pits or other in-service exposure caused the cancer.
You still need two things: a current diagnosis of a qualifying respiratory cancer, and service that meets the PACT Act's location and date criteria. See PACT Act eligibility for the current qualifying service list, and PACT Act presumptive conditions for where respiratory cancer sits among the other covered conditions. If your exposure was Agent Orange rather than burn pits — Vietnam-era or qualifying Blue Water Navy service — certain respiratory cancers are separately presumptive under the older Agent Orange rules; see our presumptive conditions overview for how the two exposure pathways differ.
Presumptive status settles how the cancer got service-connected. It does not settle what the rating will be — that comes from a separate diagnostic code.
How VA rates it: Diagnostic Code 6819
Malignant neoplasms of the respiratory system — lung cancer, bronchial cancer, and other respiratory-tract malignancies, exclusive of skin growths — are rated under Diagnostic Code 6819 in 38 CFR § 4.97, the respiratory-system rating schedule.
The 100% rating and what triggers it
DC 6819 assigns a 100% rating while the cancer is active and during treatment — surgery, chemotherapy, or radiation — and that 100% continues for six months after treatment ends. The 100% runs from the date treatment starts, not the date of diagnosis, so documenting exactly when treatment began matters for back-pay purposes.
The mandatory exam after treatment
VA schedules a mandatory examination at the end of that six-month period. That exam sets the residual rating going forward, based on whatever lasting impairment the cancer and its treatment left behind. As with other cancer diagnostic codes, a reduction from 100% is not automatic — it has to go through the notice-and-evidence procedure in 38 CFR § 3.105(e) before it takes effect.
Note also that under 38 CFR § 4.96, ratings under DC 6819 (or DC 6820, for mesothelioma-type pleural tumors) are not combined with each other or with most other respiratory diagnostic codes for the same lung or pleural involvement — VA rates the dominant residual, not each code separately.
What the rating looks like after treatment
Once the 100% period ends, the rating is rebuilt from residual lung function — not from the cancer diagnosis itself. VA rates the surviving impairment under the general rating formula for restrictive lung disease in 38 CFR § 4.97, using pulmonary function test (PFT) results: Forced Vital Capacity (FVC), FEV-1, and DLCO (diffusion capacity). Lower PFT values and greater need for outpatient oxygen or ventilatory support point to a higher residual rating. This is the same PFT-based approach used for other chronic lung conditions like asthma.
Evidence a respiratory cancer claim needs
- The pathology report. This confirms the diagnosis and the specific cancer type — imaging alone is not the same as a confirmed pathology result.
- The treatment record. The oncology record showing exactly what treatment was given, and when it started and ended, is what anchors the 100% period and the six-month exam date.
- Proof of qualifying service. For the presumptive path, your service dates and locations need to match the PACT Act (or, for Agent Orange claims, the herbicide-exposure) criteria. Your DD-214 is the starting document.
- Post-treatment pulmonary function tests. Once the 100% period ends, PFT results are what the residual rating is built from — make sure a current PFT is in the file before the mandatory exam.
If the presumptive path does not apply to your service history, respiratory cancer can still be claimed on a direct or secondary basis with a medical nexus opinion — see the nexus letter guide for what that opinion needs to say.
Common mistakes on this claim
- Filing before treatment records are complete. The 100% period is anchored to treatment dates — an incomplete record can delay or understate it.
- Skipping the post-treatment PFT. Without current pulmonary function numbers, the residual rating has nothing to be built from.
- Assuming the 100% rating is permanent. It is scheduled to be reviewed six months after treatment ends — that exam, and the evidence submitted around it, sets your ongoing rating.
- Not checking for secondary conditions. Sleep-disordered breathing and other lung-function complications can sometimes be claimed alongside a respiratory cancer residual — ask a Veterans Service Officer whether that applies to your case.
Where this fits with the rest of your claim
If residual lung impairment combines with other service-connected conditions, VA uses its combined-ratings math, not simple addition. Use the VA disability rating calculator to see what a residual rating actually does to your combined percentage. If lasting impairment prevents substantially gainful employment, ask about TDIU even if the schedular residual rating alone is below 100%.
Next step
If you have a respiratory cancer diagnosis and qualifying exposure service, confirm eligibility on the PACT Act eligibility page, then gather your pathology report and full treatment record before you file. An accredited Veterans Service Officer can file the claim with you at no cost.
This page is informational only and is not legal or medical advice. Rank and Pay is not affiliated with the Department of Veterans Affairs. Rating criteria are summarized from 38 CFR Part 4; for your specific claim, consult the VA, an accredited Veterans Service Officer (VSO), or an accredited attorney.